The clinical trial, conducted in partnership with AbbVie, tested a combination of the drug Epkinly and Bristol Myers Squibb’s Revlimid. In patients with diffuse large B-cell lymphoma who had previously undergone at least one round of treatment, the regimen significantly extended the period of progression-free survival compared to standard care.

Jefferies analysts noted that these findings match the efficacy benchmarks set by Roche’s Columvi and Lunsumio while providing the added benefit of a chemotherapy-free protocol. Beyond the immediate clinical success, the data lowers the risk profile for potential use as a first-line treatment. Genmab and AbbVie now plan to initiate discussions with global regulatory authorities to determine the path toward market authorization for this specific combination.